Gelteq Limited Ordinary Shares
GELS | NASDAQ
$0.57
+$0.01 (+1.44%)
At close: Sep 21, 2026, 4:00 PM ET
$0.55
-$0.02 (-3.51%)
Pre-market:
Sep 22, 2026, 4:18 AM ET
Company Profile
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.
Key Executives
| Name | Position |
|---|---|
| Nathan Jacob Givoni | Co-Founder, Chief Executive Officer & Executive Director |
| Thuy-Linh Gigler | Chief Financial Officer |
| Adam Bendell | President of U.S. Operations |
| Bradley Glenn Karp | Head of Sales & Marketing |
| Matthew Jones | Head of Sports Performance |
| Paul Wynne | Chief Scientific Officer |
| Simon Hayden Szewach | Co-Founder & Non-Executive Chairman |
Gelteq Limited Ordinary Shares
| Country | Australia |
| IPO Date | Oct 28, 2024 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Nathan Jacob Givoni |
Contact Details
Monash Innovation Labs, G.60, 22 Alliance Lane Clayton,
VIC 3800 Australia
Stock Details
| Ticker Symbol | GELS |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001920092 |
| CUSIP Number | n/a |
| ISIN Number | AU0000218109 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove GELS